KR102454682B1 - Tlr-4에 특이적인 압타머 및 이의 용도 - Google Patents

Tlr-4에 특이적인 압타머 및 이의 용도 Download PDF

Info

Publication number
KR102454682B1
KR102454682B1 KR1020177001493A KR20177001493A KR102454682B1 KR 102454682 B1 KR102454682 B1 KR 102454682B1 KR 1020177001493 A KR1020177001493 A KR 1020177001493A KR 20177001493 A KR20177001493 A KR 20177001493A KR 102454682 B1 KR102454682 B1 KR 102454682B1
Authority
KR
South Korea
Prior art keywords
tlr
aptamer
seq
present
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177001493A
Other languages
English (en)
Korean (ko)
Other versions
KR20170021298A (ko
Inventor
헤르난데스 이그나시오 리사소아인
무뇨스 빅또르 마누엘 곤잘레스
고메스-차꼰 게로니모 페르난데스
산체스 마리아 앙겔레스 모로
팔마 마리아 엘레나 마르틴
이베네스 아나 모랴가
Original Assignee
앱타타겟츠 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앱타타겟츠 에스.엘. filed Critical 앱타타겟츠 에스.엘.
Publication of KR20170021298A publication Critical patent/KR20170021298A/ko
Application granted granted Critical
Publication of KR102454682B1 publication Critical patent/KR102454682B1/ko
Assigned to 메르크 헬스케어 카게아아 reassignment 메르크 헬스케어 카게아아 권리의 전부이전등록 Assignors: 앱타타겟츠 에스.엘.
Assigned to 메르크 파텐트 게엠베하 reassignment 메르크 파텐트 게엠베하 권리의 전부이전등록 Assignors: 메르크 헬스케어 카게아아
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
KR1020177001493A 2014-06-24 2015-06-24 Tlr-4에 특이적인 압타머 및 이의 용도 Active KR102454682B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430955 2014-06-24
ES201430955A ES2555160B1 (es) 2014-06-24 2014-06-24 Aptámeros específicos de TLR-4 y usos de los mismos
PCT/EP2015/064277 WO2015197706A1 (en) 2014-06-24 2015-06-24 Aptamers specific for tlr-4 and uses thereof

Publications (2)

Publication Number Publication Date
KR20170021298A KR20170021298A (ko) 2017-02-27
KR102454682B1 true KR102454682B1 (ko) 2022-10-13

Family

ID=53496661

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001493A Active KR102454682B1 (ko) 2014-06-24 2015-06-24 Tlr-4에 특이적인 압타머 및 이의 용도

Country Status (18)

Country Link
US (5) US10196642B2 (enExample)
EP (1) EP3161139B1 (enExample)
JP (2) JP6959738B2 (enExample)
KR (1) KR102454682B1 (enExample)
CN (2) CN106459980B (enExample)
AU (1) AU2015279248B2 (enExample)
BR (1) BR112016030172B1 (enExample)
CA (1) CA2953020C (enExample)
DK (1) DK3161139T3 (enExample)
ES (2) ES2555160B1 (enExample)
MA (1) MA40283A (enExample)
MX (1) MX387405B (enExample)
PL (1) PL3161139T3 (enExample)
PT (1) PT3161139T (enExample)
RU (1) RU2709718C9 (enExample)
SI (1) SI3161139T1 (enExample)
WO (1) WO2015197706A1 (enExample)
ZA (1) ZA201700363B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709776B2 (en) * 2014-04-07 2020-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing outer membrane vesicles
ES2555160B1 (es) 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN113423833B (zh) * 2018-09-28 2024-09-17 奥曼尼提纳米有限公司 用于选择功能性适体的方法和组合物
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
WO2020069565A1 (en) 2018-10-02 2020-04-09 WearOptimo Pty Ltd Measurement system
US12569679B2 (en) 2018-10-02 2026-03-10 WearOptimo Pty Ltd Treatment delivery system
US12484814B2 (en) 2018-10-02 2025-12-02 WearOptimo Pty Ltd Actuator system
AU2020276703A1 (en) * 2019-05-16 2021-12-09 Merck Patent Gmbh Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
WO2021257494A1 (en) * 2020-06-15 2021-12-23 President And Fellows Of Harvard College Methods for modulating tlr4 signaling
CN114152599B (zh) * 2021-12-01 2023-10-13 中国农业大学 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器
CN114836425A (zh) * 2022-02-25 2022-08-02 温州医科大学附属眼视光医院 检测小胶质细胞的核酸适体及应用
US20260218202A1 (en) 2023-01-05 2026-07-30 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
WO2024240750A1 (en) 2023-05-22 2024-11-28 Aptatargets, S.L. New tlr-4 antagonist aptamers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053975A1 (en) 2008-11-04 2010-05-14 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 4 expression by antisense oligonucleotides
WO2010060030A1 (en) 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US248517A (en) 1881-10-18 Apparatus for transferring wood-graining
US690786A (en) 1901-09-21 1902-01-07 Andrew Stenger Bung.
US763130A (en) 1903-09-05 1904-06-21 Paul Walther Composition for artificial stone.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
WO1992005186A1 (en) 1990-09-20 1992-04-02 Gilead Sciences Modified internucleoside linkages
JPH117658A (ja) 1997-04-25 1999-01-12 Sony Corp 光学記録媒体及び光学ディスク装置
WO2001057259A1 (en) * 2000-02-03 2001-08-09 Research Development Foundation Signaling aptamers that transduce molecular recognition to a differential signal
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
CN101227922A (zh) * 2005-05-06 2008-07-23 斯克里普斯研究学院 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
EP1997902B1 (en) * 2006-03-30 2013-09-18 Hiroshima University Screening method
EA201100811A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
US9012410B2 (en) * 2006-12-13 2015-04-21 Case Western Reserve University Method of treating intrauterine inflammation
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
AU2008285626B2 (en) 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
WO2012038851A1 (en) 2010-09-24 2012-03-29 Pfizer Inc. Isoxazoline oximes as antiparasitic agents
AU2012223366B2 (en) * 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2681314B1 (en) * 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
AU2020276703A1 (en) 2019-05-16 2021-12-09 Merck Patent Gmbh Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4
US20260218202A1 (en) 2023-01-05 2026-07-30 Merck Patent Gmbh Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
WO2024240750A1 (en) 2023-05-22 2024-11-28 Aptatargets, S.L. New tlr-4 antagonist aptamers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053975A1 (en) 2008-11-04 2010-05-14 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 4 expression by antisense oligonucleotides
WO2010060030A1 (en) 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same

Also Published As

Publication number Publication date
SI3161139T1 (sl) 2020-12-31
CN106459980B (zh) 2020-11-03
CN112111495A (zh) 2020-12-22
US12655435B2 (en) 2026-06-16
EP3161139B1 (en) 2020-07-22
MX387405B (es) 2025-03-18
US11591603B2 (en) 2023-02-28
US10196642B2 (en) 2019-02-05
BR112016030172B1 (pt) 2022-11-01
RU2709718C9 (ru) 2020-02-06
RU2016152094A3 (enExample) 2019-01-29
US10808252B2 (en) 2020-10-20
PL3161139T3 (pl) 2021-01-11
MA40283A (fr) 2017-05-03
ES2555160B1 (es) 2016-10-25
WO2015197706A1 (en) 2015-12-30
ZA201700363B (en) 2018-11-28
MX2016016992A (es) 2017-05-03
US20170130227A1 (en) 2017-05-11
US20230279402A1 (en) 2023-09-07
KR20170021298A (ko) 2017-02-27
CA2953020A1 (en) 2015-12-30
JP6959738B2 (ja) 2021-11-05
JP2017527260A (ja) 2017-09-21
AU2015279248A1 (en) 2017-01-12
EP3161139A1 (en) 2017-05-03
DK3161139T3 (da) 2020-10-19
RU2709718C2 (ru) 2019-12-19
RU2016152094A (ru) 2018-07-26
BR112016030172A2 (pt) 2017-11-14
ES2555160A1 (es) 2015-12-29
JP2020127422A (ja) 2020-08-27
US20210130830A1 (en) 2021-05-06
PT3161139T (pt) 2020-10-23
ES2825106T3 (es) 2021-05-14
US20190211334A1 (en) 2019-07-11
CN106459980A (zh) 2017-02-22
US20260218204A1 (en) 2026-07-30
CA2953020C (en) 2023-01-10
AU2015279248B2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US20230279402A1 (en) Aptamers Specific for TLR-4 and Uses Thereof
JP7600208B2 (ja) 拘束された脂質を含むナノ材料およびその使用
Yerneni et al. Rapid on-demand extracellular vesicle augmentation with versatile oligonucleotide tethers
US11554097B2 (en) Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
KR102492240B1 (ko) 랑게린+ 세포 표적화
Wang et al. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy
Lu et al. Photoluminescent mesoporous silicon nanoparticles with siCCR2 improve the effects of mesenchymal stromal cell transplantation after acute myocardial infarction
Bouvain et al. Non-invasive mapping of systemic neutrophil dynamics upon cardiovascular injury
US20230088835A1 (en) Fit-flares for detection of intracellular analytes in live cells
Cai et al. Construction of Multi‐Module RNA Nanoparticles Harboring miRNA, AIE, and CH6 Aptamer for Bone Targeting and Bone Anabolic Therapy
JP2022533966A (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JPWO2009063998A1 (ja) 疎水性物質付加核酸及びその使用
WO2024026466A2 (en) Nucleic acid-based delivery systems and uses thereof
HK1240610B (en) Aptamers specific for tlr-4 and uses thereof
HK1240610A1 (en) Aptamers specific for tlr-4 and uses thereof
JP2016021883A (ja) ヒト大腸癌細胞Ｃｏｌｏ２０５に特異的に結合する核酸
EP4532722A2 (en) Mirna-based cancer therapy with a tumor-navigating peptide
Buss Nanomaterial-mediated immune interactions for disease diagnosis and cancer immunotherapy
Bouzinab Apoferritin delivery of imidazotetrazine agents for targeted brain tumour therapy
Van Woensel et al. Sensitization of glioblastoma tumor micro-environment to chemo-and immunotherapy by Galectin-1 reduction after intranasal anti-Gal-1 siRNA administration
Gray Development of Therapeutic Systems to Treat the Infarcted Heart

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)